Literature DB >> 9870879

Cytokine-regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte-lineage cells and in rheumatoid arthritis synovium.

M C Levesque1, C S Heinly, L P Whichard, D D Patel.   

Abstract

OBJECTIVE: To determine whether monocyte/macrophage expression of the CD6 ligand, activated leukocyte cell adhesion molecule (ALCAM) (CD166), is regulated by cytokines during inflammation in rheumatoid arthritis (RA).
METHODS: We used flow cytometry to test whether cytokines present in rheumatoid synovium could regulate ALCAM cell surface expression on peripheral blood (PB) monocytes and RA synovial fluid (SF) macrophages, and we examined ALCAM expression in situ in RA synovium by immunofluorescence.
RESULTS: The monocyte differentiation factors interleukin-3, macrophage colony-stimulating factor (M-CSF), and granulocyte-macrophage colony-stimulating factor augmented ALCAM expression on PB monocytes. ALCAM was expressed on monocyte-lineage cells in situ in inflamed synovium from patients with RA (9 of 9), but not in uninflamed synovium from patients with joint trauma (0 of 3). Furthermore, in vitro culture-induced ALCAM expression on PB monocytes and CD14+ RA SF cells was inhibited by an M-CSF neutralizing antibody.
CONCLUSION: ALCAM expression on PB and SF monocytes/macrophages is enhanced by M-CSF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870879     DOI: 10.1002/1529-0131(199812)41:12<2221::AID-ART18>3.0.CO;2-I

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

1.  Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin.

Authors:  L C van Kempen; J J van den Oord; G N van Muijen; U H Weidle; H P Bloemers; G W Swart
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  CD166 expression, characterization, and localization in salivary epithelium: implications for function during sialoadenitis.

Authors:  Syed M A Abidi; Mohammad K Saifullah; Marie D Zafiropulos; Cara Kaput; Michael A Bowen; Calvin Cotton; Nora G Singer
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

3.  Identifying molecular phenotype of nucleus pulposus cells in human intervertebral disc with aging and degeneration.

Authors:  Xinyan Tang; Liufang Jing; William J Richardson; Robert E Isaacs; Robert D Fitch; Christopher R Brown; Melissa M Erickson; Lori A Setton; Jun Chen
Journal:  J Orthop Res       Date:  2016-04-13       Impact factor: 3.494

4.  Dynamic regulation of activated leukocyte cell adhesion molecule-mediated homotypic cell adhesion through the actin cytoskeleton.

Authors:  J M Nelissen; I M Peters; B G de Grooth; Y van Kooyk; C G Figdor
Journal:  Mol Biol Cell       Date:  2000-06       Impact factor: 4.138

5.  Attenuation of Murine Collagen-Induced Arthritis by Targeting CD6.

Authors:  Yan Li; Jeffrey H Ruth; Stephanie M Rasmussen; Kalana S Athukorala; Daniel P Weber; M Asif Amin; Phillip L Campbell; Nora G Singer; David A Fox; Feng Lin
Journal:  Arthritis Rheumatol       Date:  2020-08-14       Impact factor: 10.995

6.  Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease.

Authors:  R Yamada; T Tanaka; M Unoki; T Nagai; T Sawada; Y Ohnishi; T Tsunoda; M Yukioka; A Maeda; K Suzuki; H Tateishi; T Ochi; Y Nakamura; K Yamamoto
Journal:  Am J Hum Genet       Date:  2001-02-14       Impact factor: 11.025

7.  CD166/ALCAM mediates proinflammatory effects of S100B in delayed type hypersensitivity.

Authors:  Rüdiger von Bauer; Dimitrios Oikonomou; Alba Sulaj; Sawsan Mohammed; Agnes Hotz-Wagenblatt; Hermann-Josef Gröne; Bernd Arnold; Christine Falk; Dorit Luethje; Axel Erhardt; David M Stern; Angelika Bierhaus; Peter P Nawroth
Journal:  J Immunol       Date:  2013-05-31       Impact factor: 5.422

8.  Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).

Authors:  Christelle Le Dantec; Ruby Alonso; Tinhinane Fali; Enrique Montero; Valérie Devauchelle; Alain Saraux; Jacques-Olivier Pers; Yves Renaudineau
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

9.  The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.

Authors:  P C Rodríguez; D M Prada; E Moreno; L E Aira; C Molinero; A M López; J A Gómez; I M Hernández; J P Martínez; Y Reyes; J M Milera; M V Hernández; R Torres; Y Avila; Y Barrese; C Viada; E Montero; P Hernández
Journal:  Clin Exp Immunol       Date:  2017-11-16       Impact factor: 4.330

10.  Syntenin-1 and ezrin proteins link activated leukocyte cell adhesion molecule to the actin cytoskeleton.

Authors:  Cicerone Tudor; Joost te Riet; Christina Eich; Rolf Harkes; Nick Smisdom; Jessica Bouhuijzen Wenger; Marcel Ameloot; Matthew Holt; Johannes S Kanger; Carl G Figdor; Alessandra Cambi; Vinod Subramaniam
Journal:  J Biol Chem       Date:  2014-03-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.